Cardinal completes Pyxis acquisition for $952 mil. in stock.
CARDINAL ACQUISITION OF PYXIS FOR $952 MIL. IN STOCK CLOSES May 7, the drug distributor announced. Pyxis shareholders received .4 shares of Cardinal Health stock for each Pyxis share; the May 6 closing price for Cardinal was $63.38. Approximate closing costs for the acquisition are $17 mil., according to the registration statement for the merger filed with the Securities & Exchange Commission. Additional merger-related costs could amount to $10 mil. to $15 mil., the registration statement says.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth